ArticlePloS one2026
Computational models for the classification of antibody specificity using heavy chain features.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntibodies play a critical role in immune defense, with their antigen specificity primarily governed by the unique sequences of their heavy chains, rendering them invaluable tools in research and diagnostics. High-throughput sequencing technologies have facilitated comprehensive profiling of the immune repertoire, generating vast antibody sequence datasets that necessitate advanced analytical methods.
methodsIn this study, we utilized curated antibody sequences from NCBI databases to develop computational classification models for categorizing antibodies into predefined antigen classes. We extracted multifaceted features from the heavy chain sequences, encompassing physicochemical properties, structural composition, sequence order, and evolutionary information. These features were input into machine-learning classifiers to predict antigen specificity across five classes of antibodies: anti-dengue virus, anti-influenza virus, anti-tetanus bacillus, anti-SARS-CoV-2, and anti-Mycobacterium tuberculosis.
resultsFive tree-based machine-learning models were employed, with CatBoost achieving the highest accuracy of 0.7713. To further enhance predictive performance, we developed a stacking model leveraging multiple algorithms, resulting in an improved accuracy of 0.7803. Additionally, a Feature-Based Transformer deep-learning architecture was implemented, yielding an accuracy of 0.7399 and an F1-score of 0.6761. To elucidate the key determinants of antibody-antigen interactions, we applied the SHAP framework to assess feature importance. Among the top 30 contributing features, those representing sequence order and evolutionary information predominated, with amino acids such as cysteine (C), isoleucine (I), histidine (H), and phenylalanine (F) exhibiting notable SHAP values. Notably, cysteine (Cys) emerged as the most influential feature, underscoring its critical role in antibody structure and function. Specific antibodies contributed variably to these key features; for instance, the anti-tuberculosis antibody accounted for approximately 11% of a sequence order feature associated with alanine (A), while the anti-SARS-CoV-2 antibody contributed about 9.26% to a feature associated with isoleucine (I).
conclusionsOur study demonstrates the efficacy of machine-learning and deep-learning approaches in classifying antibodies into specific antigen categories, providing sequence-based insights into features associated with antibody specificity. These findings have significant implications for the mechanistic understanding, isolation, and development of potential therapeutic antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.